Intravenous Rh immune globulin prevents alloimmunization in D– granulocyte recipients but obscures the detection of an alloanti-K


Share / Export Citation / Email / Print / Text size:


American National Red Cross

Subject: Medical Laboratory Technology


ISSN: 0894-203X
eISSN: 1930-3955





Volume / Issue / page

Volume 37 (2021)
Volume 36 (2020)
Volume 35 (2019)
Volume 34 (2018)
Volume 33 (2017)
Volume 32 (2016)
Volume 31 (2015)
Volume 30 (2014)
Volume 29 (2013)
Volume 28 (2012)
Volume 27 (2011)
Volume 26 (2010)
Volume 25 (2009)
Volume 24 (2008)
Volume 23 (2007)
Volume 22 (2006)
Volume 21 (2005)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2002)
Volume 17 (2001)
Volume 16 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1996)
Volume 11 (1995)
Volume 10 (1994)
Volume 9 (1993)
Volume 8 (1992)
Volume 7 (1991)
Volume 6 (1990)
Volume 5 (1989)
Volume 4 (1988)
Volume 3 (1987)
Related articles

VOLUME 17 , ISSUE 2 (June 2001) > List of articles

Intravenous Rh immune globulin prevents alloimmunization in D– granulocyte recipients but obscures the detection of an alloanti-K

D.F. Stroncek / J.L. Procter / L. Moses / C. Bolan / G.J. Pomper / C. Conry-Cantilens / H.L. Malech / H.G. Klein / S.F. Leitman

Keywords : granulocytes, granulocyte transfusions, intravenous immune globulin, Rh immune globulin, Rh alloimmunization, Rh D, transfusion reactions

Citation Information : Immunohematology. Volume 17, Issue 2, Pages 37-41, DOI:

License : (Transfer of Copyright)

Published Online: 14-October-2020



Rh immune globulin (RhIG) has been used to prevent alloimmunization in D– recipients of apheresis platelet transfusions from D+ donors that may contain up to 5 mL of D+ red blood cells (RBCs). Granulocyte concentrates contain approximately 30 mL of RBCs and it has been necessary to give D– recipients granulocyte transfusions from D+ donors. Intravenous RhIG has not yet been demonstrated to be effective in preventing D alloimmunization with granulocyte transfusions. Four D– recipients received multiple D+ granulocyte transfusions from D+ donors and multiple injections of intravenous RhIG at a standard dose of 600 μg for each D+ transfusion. Two D– males with chronic granulomatous disease were given 32 and 13 daily granulocyte transfusions, 18 and 2 of which, respectively, were D+. After the first dose of intravenous RhIG, both patients exhibited circulating anti-D that was undetectable 3 to 4 years later. Two patients with severe aplastic anemia were given 5 and 14 granulocyte transfusions, 4 and 7 of which, respectively, were D+. Both patients died before the effectiveness of RhIG could be assessed. In one of these patients the indirect and direct antiglobulin tests became positive after the first dose of intravenous RhIG, which required that subsequent granulocyte transfusions from D+ donors be crossmatched by immediate spin (IS) testing only. A delayed hemolytic reaction attributed to alloanti-K occurred after granulocytes from a K+ donor were given to this patient. These results suggest that intravenous RhIG can be used to prevent alloimmunization to D in D– patients receiving large quantities of RBCs from D+ granulocyte transfusions. However, anti-D and other passive antibodies from RhIG prohibit the use of the antiglobulin crossmatch with antigenpositive granulocyte donor samples. It may be important to frequently collect new samples to screen for newly formed alloantibodies when IS crossmatches are used in place of the antiglobulin crossmatch.

You don't have 'Full Text' access of this article.

Purchase Article Subscribe Journal Share